Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

Abstract

There is 10 years of marketing experience with the hepatitis A vaccine Havrix™. It is highly immunogenic, provides lasting protection in healthy individuals and generates protective levels of antibodies in patients with chronic liver disease or impaired immunity. Postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. The timing of the booster dose is not critical to effectiveness, which has advantages for the protection of travelers to regions of high endemicity. The vaccine is effective in curbing outbreaks of hepatitis A and also when administered postexposure, due to rapid seroconversion and the long incubation period of the disease. In intermediate endemic regions, an epidemiological shift in hepatitis A infection has driven the development of universal preventive strategies to be added to the targeting of at-risk groups. Existing official recommendations and future directions for vaccine use are reviewed.

• cost-effectiveness
• Havrix™
• hepatitis A
• long-term protection
• prevention
• vaccination